The 2023 U.S. Cancer Report suggests that the incidence of prostate cancer (PCa) declined by approximately 40% from 2007 to 2014, possibly due to a decline in the value of diagnosing localized tumors by testing for prostate-specific antigen (PSA) [1]. This evidence concerns the gene KLK3 and prostate carcinoma.